Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety Study of a Radiolabeled Antibody (7E11) in Patients With Progressive Hormone Refractory Prostate Cancer (CYT-500)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2007 by Cytogen Corporation.
Recruitment status was:  Recruiting
Sponsor:
Information provided by:
Cytogen Corporation
ClinicalTrials.gov Identifier:
NCT00441571
First received: February 27, 2007
Last updated: September 6, 2007
Last verified: September 2007
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: No date given